Cancer stem cell-like characteristics of a CD133+ subpopulation in the J82 human bladder cancer cell line

Huang,Peng; Watanabe,Masami; Kaku,Haruki; Ueki,Hideo; Noguchi,Hirofumi; Sugimoto,Morito; Hirata,Takeshi; Yamada,Hiroshi; Takei,Kohji; Zheng,Shaobo; Xu,Kai; Nasu,Yasutomo; Fujii,Yasuyuki; Liu,Chunxiao; Kumon,Hiromi

doi:10.3892/mco.2012.29

Cancer stem cell-like characteristics of a CD133+ subpopulation in the J82 human bladder cancer cell line

Authors:
- Peng Huang
- Masami Watanabe
- Haruki Kaku
- Hideo Ueki
- Hirofumi Noguchi
- Morito Sugimoto
- Takeshi Hirata
- Hiroshi Yamada
- Kohji Takei
- Shaobo Zheng
- Kai Xu
- Yasutomo Nasu
- Yasuyuki Fujii
- Chunxiao Liu
- Hiromi Kumon
View Affiliations

Affiliations: Center for Gene and Cell Therapy, Okayama University, Okayama, Japan, Department of Urology, Okayama University, Okayama, Japan, Department of Gastroenterological Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan, Department of Neuroscience, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan, Department of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, P.R. China, Innovation Center Okayama for Nanobio-Targeted Therapy, Okayama University, Okayama, Japan
Published online on: September 26, 2012 https://doi.org/10.3892/mco.2012.29
Pages: 180-184

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cancer stem cells (CSCs) are thought to be crucial for understanding the biological roots of cancer, and are of increasing importance as a target for new anticancer agents. According to an expression analysis of the cell surface antigens of various types of cancer, CD133 is considered to be a potential marker of cancer stemness. In this study, a human urinary bladder cancer cell line (J82) was used to analyze the cancer stem cell-like characteristics of CD133+ bladder cancer cells in vitro and in vivo. The CD133 expression in the J82 cells was examined and the cells were immunomagnetically categorized into positive and negative subsets. The CD133- and CD133+ subsets were phenotypically divergent with regard to the cell growth pattern, while CD133+ cells tended to colonize during their growth. In CD133+ cells, the pluripotent stem cell factors Oct-4 and Sox-2 were upregulated, and a statistically significant proliferation increase was observed when compared to CD133- cells. The CD133+ subpopulation was more tolerant to the chemotherapeutic agent cisplatin, and Bacillus Calmette-Guérin (BCG), an agent instilled intravesically to treat bladder cancer. In addition, CD133+ J82 cells were more resistant to radiation treatment when compared to CD133- cells. The in vivo tumorigenesis of the CD133- and CD133+ subsets of J82 cancer cells was also examined by subcutaneously injecting them into nude mice. The tumor growth was more aggressive in the CD133+ subpopulation, showing a significant difference in the tumorigenic potential in these subsets. In conclusion, J82 human bladder cancer cells include CD133- and CD133+ subpopulations, while the CD133 molecule is a potential marker of the potential malignancy of human bladder cancer. In the present study, the CD133+ subpopulation was herein demonstrated to have certain characteristics consistent with those of cancer stem cells.

View Figures

View References

1.	Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell. 144:646–674. 2011.
2.	Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C and De Maria R: Identification and expansion of human colon-cancer-initiating cells. Nature. 445:111–115. 2007.
3.	Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, Shelton AA, Parmiani G, Castelli C and Clarke MF: Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA. 104:10158–10163. 2007.
4.	Monzani E, Facchetti F, Galmozzi E, Corsini E, Benetti A, Cavazzin C, Gritti A, Piccinini A, Porro D, Santinami M, Invernici G, Parati E, Alessandri G and La Porta CA: Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer. 43:935–946. 2007.
5.	Immervoll H, Hoem D, Sakariassen PØ, Steffensen OJ and Molven A: Expression of the ‘stem cell marker’ CD133 in pancreas and pancreatic ductal adenocarcinomas. BMC Cancer. 8:482008.
6.	Marhaba R, Klingbeil P, Nuebel T, Nazarenko I, Buechler MW and Zoeller M: CD44 and EpCAM: cancer-initiating cell markers. Curr Mol Med. 8:784–804. 2008.
7.	Wu Y and Wu PY: CD133 as a marker for cancer stem cells: progresses and concerns. Stem Cells Dev. 18:1127–1134. 2009.
8.	An Y and Ongkeko WM: ABCG2: the key to chemoresistance in cancer stem cells? Expert Opin Drug Metab Toxicol. 5:1529–1542. 2009.
9.	Lathia JD, Gallagher J, Heddleston JM, Wang J, Eyler CE, Macswords J, Wu Q, Vasanji A, McLendon RE, Hjelmeland AB and Rich JN: Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell. 6:421–432. 2010.
10.	Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, Olweus J, Kearney J and Buck DW: AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood. 90:5002–5012. 1997.
11.	Guzmán-Ramírez N, Völler M, Wetterwald A, Germann M, Cross NA, Rentsch CA, Schalken J, Thalmann GN and Cecchini MG: In vitro propagation and characterization of neoplastic stem/progenitor-like cells from human prostate cancer tissue. Prostate. 69:1683–1693. 2009.
12.	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010.
13.	Ueki H, Watanabe M, Kaku H, Huang P, Li SA, Ochiai K, Hirata T, Noguchi H, Yamada H, Takei K, Nasu Y, Kashiwakura Y and Kumon H: A novel gene expression system for detecting viable bladder cancer cells. Int J Oncol. 41:135–140. 2012.
14.	Hirata T, Watanabe M, Kaku H, Kobayashi Y, Yamada H, Sakaguchi M, Takei K, Huh NH, Nasu Y and Kumon H: REIC/ Dkk-3 encoding adenoviral vector as a potentially effective therapeutic agent for bladder cancer. Int J Oncol. 41:559–564. 2012.
15.	Watanabe M, Ueki H, Ochiai K, Huang P, Kobayashi Y, Nasu Y, Sasaki K, Kaku H, Kashiwakura Y and Kumon H: Advanced two-step transcriptional amplification as a novel method for cancer-specific gene expression and imaging. Oncol Rep. 26:769–775. 2011.
16.	Bidlingmaier S, Zhu X and Liu B: The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells. J Mol Med (Berl). 86:1025–1032. 2008.
17.	Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, Van Belle PA, Xu X, Elder DE and Herlyn M: A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res. 65:9328–9337. 2005.
18.	Levina V, Marrangoni AM, DeMarco R, Gorelik E and Lokshin AE: Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One. 3:e30772008.
19.	Chen YC, Hsu HS, Chen YW, Tsai TH, How CK, Wang CY, Hung SC, Chang YL, Tsai ML, Lee YY, Ku HH and Chiou SH: Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PloS One. 3:e26372008.
20.	Walter D, Satheesha S, Albrecht P, Bornhauser BC, D’Alessandro V, Oesch SM, Rehrauer H, Leuschner I, Koscielniak E, Gengler C, Moch H, Bernasconi M, Niggli FK and Schäfer BW; CWS Study Group: CD133 positive embryonal rhabdomyosarcoma stem-like cell population is enriched in rhabdospheres. PloS One. 6:e195062011.
21.	Dean M, Fojo T and Bates S: Tumour stem cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005.
22.	Marques DS, Sandrini JZ, Boyle RT, Marins LF and Trindade GS: Relationships between multidrug resistance (MDR) and stem cell markers in human chronic myeloid leukemia cell lines. Leuk Res. 34:757–762. 2010.
23.	Chiou SH, Kao CL, Chen YW, Chien CS, Hung SC, Lo JF, Chen YJ, Ku HH, Hsu MT and Wong TT: Identification of CD133-positive radioresistant cells in atypical teratoid/rhabdoid tumor. PloS One. 3:e20902008.
24.	Blazek ER, Foutch JL and Maki G: Daoy medulloblastoma cells that express CD133 are radioresistant relative to CD133⁻ cells, and the CD133⁺ sector is enlarged by hypoxia. Int J Radiat Oncol Biol Phys. 67:1–5. 2007.
25.	Fong YW, Inouye C, Yamaguchi T, Cattoglio C, Grubisic I and Tjian R: A DNA repair complex functions as an Oct4/Sox2 coactivator in embryonic stem cells. Cell. 147:120–131. 2011.